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Background: Visceral fat possesses the most detrimental potential for cardiovascular morbidity through the release
of adipokines, as well as metabolic and proinflammatory mediators, which adversely affect metabolic and vascular
homeostasis. Among the different types of visceral adipose tissue, mesenteric fat is considered particularly
detrimental, due to its close proximity to the portal circulation, affecting directly the liver, which is the main
regulator of body metabolic homeostasis. Mesenteric fat can be reliably estimated using abdominal
ultrasonography, the only available imaging method able to depict individual mesenteric leaves. Aim of the present
study was to investigate the correlation of mesenteric fat thickness (MFT) with serum apolipoprotein levels in
patients undergoing digital subtraction angiography in a single center.
Methods: 35 male patients with peripheral arterial disease were examined. After careful examination of the
periumbilical area, the mesenteric leaves were identified. The maximal distance between each pair of sequential
leaves was measured, and the mean value of the three thickest leaves was determined as the mesenteric fat
thickness. Six apolipoprotein fasting serum concentrations were measured using a Luminex proteomics platform
(xMAP Multiplex immunoassay): apolipoprotein A-I (apoAI), apolipoprotein A-II (apoAII), apolipoprotein B (apoB),
apolipoprotein C-II (apoCII), apolipoprotein C-III (apoCIII) and apolipoprotein E (apoE).
Results: MFT correlated with apoAII and apoB serum concentrations. The correlations with apoAII and apoB
remained significant following correction for BMI. No correlations were noted between MFT and serum apoAI,
apoCII, apoCIII or apoE levels before or after adjustment for BMI.
Conclusions: Our study indicates that MFT is significantly correlated with the concentration of atherogenic low
density lipoproteins particles, as well as with apoAII, a determinant of free fatty acids levels. No correlation was
observed between mesenteric fat thickness and very low density lipoprotein or chylomicron particles concentration.
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Table 1 Patient characteristics
Parameter Frequency (%)





Age (years) 64.4 ± 10.0
Weight (kg) 78.0 ± 9.7
BMI (kg/m2) 26.8 ± 2.7
Total Cholesterol (mg/dl) 205.7 ± 67.5
LDL Cholesterol (mg/dl) 134.5 ± 68.6
Triglycerides (mg/dl) 166.4 ± 82.6
Apolipoprotein A-I (mg/dl) 179.3 ± 50.1
Apolipoprotein A-II (mg/dl) 35.5 ± 18.2
Apolipoprotein B (mg/dl) 76.3 ± 50.2
Apolipoprotein C-II (mg/dl) 6.9 ± 4.2
Apolipoprotein C-III (mg/dl) 19.8 ±10.6
Apolipoprotein E (mg/dl) 5.8 ± 2.4
Mesenteric Fat Thickness (cm) 0.73 ± 0.41
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Obesity has emerged as a global pandemic, recently
characterized by the World Health Organization as
globesity [1]. Its rates are increasing worldwide, with
almost 25% and 10% of the global population being
overweight and obese, respectively [2]. Obesity has
been linked to a large number of diseases, including
diabetes mellitus, cardiovascular diseases and numer-
ous forms of cancer [3].
There is an increasing amount of evidence demon-
strating that regional rather than total adiposity is a
more significant factor for obesity related disorders. Vis-
ceral fat possesses the most detrimental potential for
cardiovascular morbidity through the release of adipo-
kines, as well as metabolic and proinflammatory media-
tors, which adversely affect metabolic and vascular
homeostasis [4]. Among the different types of visceral
adipose tissue, mesenteric fat is considered particularly
detrimental, due to its close proximity to the portal cir-
culation, affecting directly the liver, which is the coord-
inator of body metabolic regulation [5].
Mesenteric fat can be reliably estimated using abdom-
inal ultrasonography, the only available imaging method
able to depict individual mesenteric leaves [5]. Until
today, mesenteric fat has been correlated with metabolic
and cardiovascular markers, such as blood lipoprotein
concentrations [5]. However, there are no available stud-
ies investigating the possible influence of mesenteric fat
to specific apolipoproteins, constituents of serum lipo-
proteins and key molecules to their function.
Apolipoprotein A-I (apoAI) is the major structural
component of high density lipoprotein (HDL), exhibiting
significant atheroprotective functions [6]. Apolipoprotein
A-II (apoAII) is the second most important protein
component of HDL and seems to have a significant role
in triglyceride metabolism [7]. Its levels have been corre-
lated with fat distribution in humans [7]. Apolipoprotein
B (apoB) is the major protein constituent of the athero-
genic low density lipoprotein (LDL), intermediate density
lipoprotein (IDL), very low density lipoprotein (VLDL)
and of chylomicrons [6]. It has been proposed that serum
apoB concentration may be a more reliable marker than
serum LDL determination, since it can be directly mea-
sured, rather than estimated through a relevant formula [6].
Apolipoprotein C-II (apoCII) is a protein component of
VLDL and contains a cofactor for lipoprotein lipase, which
hydrolyzes triglycerides into fatty acids [8]. In humans,
hypertriglyceridemia is regularly accompanied by a signifi-
cant increase in apoCII plasma levels. Apolipoprotein C-III
(apo CIII) is an inhibitor of lipoprotein lipase and of trigly-
cerides remnant uptake by hepatic lipoprotein recep-
tors [9], as well as a component of chylomicrons, VLDL,
IDL and LDL. Its levels have been show to correlate
with the degree of insulin resistance, while apoCIIIoverexpression has been found to accelerate the progress
of atherosclerosis in rodents [9]. Finally, apolipoprotein E
(apoE) is the main ligand for clearance of VLDL and
chylomicron remnants, affecting the circulating concen-
trations of lipoproteins and plasma levels of cholesterol
and triglycerides [10].
Aim of the present study was to investigate the correl-
ation of mesenteric fat thickness (MFT) with serum apoli-
poprotein levels in patients undergoing digital subtraction
angiography in a single center. Specifically, 6 apolipoprotein
serum concentrations were measured using a Luminex pro-
teomics platform: apoAI, apoAII, apoB, apoCII, apoCIII
and apoE.Results
The patient group (n = 35) was comprised of 25.7%
(n = 9) women and 74.3% (n = 26) men. Mean participant
age was 65.5 ± 10.0 years. All patient characteristics
(n = 35) are depicted in Table 1.
Mean MFT was 0.73 ± 0.4 cm. There were no statisti-
cally significant differences in MFT between the two
sexes, even after correction for BMI and BMI and age
(Table 2).
In a multivariate analysis, no significant differences
were detected in MFT measurements between patient
subgroups, formed based on previous angioplasty, hyper-
tension and presence of dyslipedemia, even after correc-
tion for BMI and BMI and age (Table 2). MFT correlated
Table 2 Comparison of mesenteric fat thickness (in mm) between patient subgroups
Grouping Parameter Males Females Significance Level
Sex 0.72 ± 0.43 (n = 26) 0.76 ± 0.4 (n = 9) 0.62 (NS)
Grouping Parameter Group (+) Group (−) Significance Level
Hypertension 0.71 ± 0.4 (n = 24) 0.84 ± 0.5 (n = 11) 0.59 (NS)
Dyslipidemia 0.7 ± 0.37 (n = 20) 0.82 ± 0.52 (n = 15) 0.77 (NS)
Previous Angioplasty 0.74 ± 0.5 0.74 ± 0.42 0.85 (NS)
NS Non Significant.
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The correlations with apoAII and apoB remained sig-
nificant following correction for BMI (Table 3). No
correlations were noted between MFT and serum
apolipoproteins apoAI, apoCII, apoCIII or apoE before
or after adjustment for BMI (Table 3).
Discussion
Obesity, defined by the WHO as BMI > 30, is considered
as one of the major preventable causes of death world-
wide and is characterized by a positive disequilibrium
between energy intake and energy expenditure [11]. It is
directly involved in the pathogenesis of insulin resist-
ance, atherosclerosis, dyslipidemia, hypertension and de-
generative joint disease [2]. Research conducted in the
past few decades has revealed the pleiotropic effects
of adipose tissue on every aspect of bodily functions
and homeostasis, including immunity, metabolism and
aging [12].
Mesenteric fat can be accurately and reliably assessed
by ultrasonography, using the methodology described by
Liu et al. [13]. This method requires significant training
by experienced physicians [14]. However, if properly
trained, the intra- and inter- operator variability is low
[13,15-17]. The presence of obesity does not negatively
affect the reliability of the imaging modality, since
increased adipose tissue accumulation renders mesen-
teric leaves readily visible [18].
The estimation of MFT ultrasonographically is one of
the newest additions to the array of available imaging
techniques for adipose tissue estimation. MFT has
demonstrated positive associations with indices of insulin
resistance (ie fasting blood glucose, HOMA-IR index, fast-
ing serum insulin) [13,17,19] and subclinical atheroscler-
osis (carotid intima-media thickness) [13,15]. Increased
MFT has been proposed as a significant prognostic factorTable 3 Correlation between MFT and Serum apolipoprotein
Correlation with MFT apoAI apoAII
Correlation Coefficient (Significance Level) 0.28 (NS) r = 0.5 (p < 0.
Correlation with MFT (corrected for BMI) apoAI apoAII
Correlation Coefficient (Significance Level) 0.28 (NS) r = 0.45 (p < 0
NS Non significant.for polycystic ovary syndrome and fatty liver, conditions
directly linked to insulin resistance, the metabolic syn-
drome, as well as atherosclerosis [16,19].
Even though MFT has been correlated to LDL and
HDL serum concentrations [13,17], no studies have
been carried out regarding the relationship between
MFT and lipoprotein subfractions or serum concentra-
tions. To our knowledge, this is the first available study
to investigate the correlation of MFT to a large array of
apolipoproteins.
Much attention has been devoted to the effect of
apolipoproteins on the progression of atherosclerosis
[6]. They act as cofactors for enzymes involved in lipid
metabolism, ligands for receptors or mediators of re-
verse cholesterol transport. Assessment of apolipoprotein
levels is useful in predicting risk of cardiovascular
disease [6].
Mesenteric fat may have a significant effect on serum
lipoproteins by modulating liver function. It is the only
adipose tissue depot that drains to the portal circulation,
thus directly affecting liver metabolism and biosynthetic
activity. It promotes liver fat accumulation and insulin
resistance, which in turn leads to elevated hepatic glu-
cose production and increased release of free fatty acids
(FFAs) from adipose tissue [20,21].
Abdominal fat cell weight has been previously reported
to negatively correlate with plasma apoAI concentra-
tion [22]. However, in our study we did not observe a
statistically significant relationship of MFT with apoAI
levels. On the other hand, MFT measurements correlated
linearly with apoAII serum concentrations. This correl-
ation may reflect the role of mesenteric fat as a significant
source of triglycerides in the fasting state. A study in-
vestigating the impact of weight loss on HDL apoAII
kinetics in the metabolic syndrome reported a signifi-
cant correlation between changes in apoAII fractionallevels
apoB apoCII apoCIII apoE
01) r = 0.47 (p < 0.01) −0.06 (NS) −0.04 (NS) 0.06 (NS)
apoB apoCII apoCIII apoE
.01) r = 0.44 (p < 0.05) −0.08 (NS) −0.07 (NS) 0.06 (NS)
Perelas et al. Lipids in Health and Disease 2012, 11:125 Page 4 of 6
http://www.lipidworld.com/content/11/1/125catabolic rate and visceral adipose tissue mass, indi-
cating a potential role for adiposity in the regulation
of apoAII catabolism [23].
In our study, we also observed a significant correlation
between MFT and apoB levels, the major component of
LDL lipoproteins. FFAs released by mesenteric fat have
been shown to increase apoB production and VLDL re-
lease. VLDL is transformed into IDL and LDL, a process,
which results in the production of atherogenic LDL lipo-
proteins containing apoB [24-26]. Mesenteric adipose
tissue may be a significant source of FFAs in both the
fasting and fed period, given its relative resistance to the
lipotrophic effects of insulin and its sensitivity to the
lipolytic effects of catecholamines [4,27]. These effects
may be exaggerated in individuals with increased mesen-
teric adipose tissue depots.
As far as the other secretory products of mesenteric
fat are concerned, interleukin- 6 and tumor necrosis fac-
tor alpha have been shown to increase apoB and VLDL
production by hepatocytes in both clinical and experi-
mental studies [25,28-31].
On the other hand, no statistically significant correla-
tions were observed between mesenteric fat thickness
and components of VLDL lipoproteins, such as apoCII
or apoCIII. This lack of association may be attributed to
the design of the study. During the fasting state, VLDL
lipoprotein levels tend to be diminished, and this may
interfere with the possible relationship between mesen-
teric adipose tissue and liver lipoprotein production. In a
previous study and in accordance to our results, serum
apoE levels did not differ between obese and non-obese
individuals [32]. However, visceral fat accumulation sig-
nificantly correlated with serum apoE concentration in
middle-aged non-obese Japanese men [33].
The role of mesenteric fat on inflammation and oxida-
tive damage in vascular tissue and the correlation of its
thickness with cardiovascular disease risk are documen-
ted in literature [34]. Trying to extend the existing
knowledge, our study showed that MFT significantly cor-
relates with apoB and apoAII levels. The correlation
with apoB confirms the close association between MFT
and atherosclerotic risk, observed in a significant num-
ber of previous studies. The correlation of MFT with
apoAII may reflect the role of mesenteric fat as a signifi-
cant source of triglycerides in the fasting state.
Conclusion
Our study indicates that MFT significantly correlates
with the concentration of atherogenic LDL apoB parti-
cles, as well as with apoAII, a determinant of free fatty
acids levels. Our data are in concordance to that of pre-
vious studies and demonstrate the significance of vis-
ceral adipose tissue as an atherosclerosis risk factor.
Further investigation of the pathogenic and regulatorypathways of visceral obesity that promote atherosclerotic
procedures is needed and may reveal new targets for
atherosclerosis prevention and treatment.Methods
Patient population consisted of individuals with peripheral
vascular disease (PVD) admitted to the Interventional
Radiology Clinic of the University Hospital “Aretaieion”
between April 2009 and May 2010 to undergo intra-
arterial digital subtraction angiography. The study proto-
col was approved by the hospital's Ethics Commiteee
(no. M-117 / 07-02-2008). The diagnosis of PVD was
based on physical examination findings, clinical symp-
toms, measurement of the ankle- brachial index and
duplex ultrasound scanning. Patients with recent cardio-
vascular or cerebrovascular event (myocardial infarction,
cerebral infarction or hemorrhage), malignant disease,
diabetes mellitus, renal failure or chronic inflammatory
bowel disease (Crohn's disease or ulcerative colitis) were
excluded from the study. Every other eligible patient was
enrolled to the study. All study participants provided their
written informed consent and they completed a question-
naire on demographic factors, eating habits and medical
history. Height was measured by using a fixed stadi-
ometer. Body weight was measured to the nearest hecto-
gram. Fasting blood samples (20 ml venous blood)
were collected prior to the angiographic examination.
Fasting serum apolipoprotein (apoAI, apoAII, apoB,
apoCII, apoCIII and apoE) concentrations were mea-
sured using Luminex xMAP immunoassay (Luminex
Corp., Austin, TX, USA) 6-plex panel (Merch Millipore,
MA, USA).
On the same day, each participant was subjected to
abdominal ultrasound scans by the same experienced
radiologist, who was unaware of the subjects’ clinical
and laboratory characteristics. The radiologist followed
the methodology of Liu et al. for mesenteric fat estima-
tion, using a 5–7 MHz linear-array transducer [13].
Briefly, the subjects were placed in a supine position and
were asked to hold their breath during the measure-
ments. The whole abdomen was scanned with emphasis
in the periumbilical area, as more mesenteries are
located in that area and can be easily identified. The
mesenteric leaves appear as elongated structures with
highly reflective peritoneal surfaces (Figure 1). Not all
the mesenteries are visualized clearly during the examin-
ation, since some can be obscured by bowel gas. Usually,
6–10 measurements were performed during each ultra-
sound examination and the mean value of the three
thickest mesenteric leaves was used for the analysis. A
typical ultrasound examination would require 10–15
minutes by an experienced to the specific technique
radiologist.
Figure 1 Mesenteric fat thickness measurement/ detailed
legend: mesenteric fat thickness estimated by ultrasonography.
The mesenteric leaves are indicated by crosses.
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The present study identified statistically significant cor-
relations between MFT and serum apolipoproteins in
PVD patients. However, future comparative studies using
large numbers of patients and healthy subjects are ne-
cessary, in order to examine differences between sub-
groups and to derive useful further information. The use
of fasting blood samples may have obscured a possible
relationship of MFT and VLDL components. By per-
forming single operator evaluations we avoided inter-
but not intra-operator variability.Competing interests
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